Results 161 to 170 of about 3,573 (200)

Erenumab

Reactions Weekly
  +8 more sources

Erenumab

Reactions Weekly, 2019
  +6 more sources

Erenumab: First Global Approval

Drugs, 2018
Amgen and Novartis are developing erenumab (AIMOVIG™, erenumab-aooe)-a fully human monoclonal antibody calcitonin gene-related peptide (CGRP) receptor antagonist-for the prevention of migraine. CGRP is a vasodilatory neuropeptide implicated in the pathophysiology of migraine and treatment with erenumab was associated with significant reductions in ...
openaire   +2 more sources

Erenumab for episodic migraine prophylaxis

Expert Review of Neurotherapeutics, 2019
Introduction: This paper reviews placebo-controlled randomized double-blind studies with erenumab for the prevention of migraine. Erenumab is a fully human monoclonal antibody (mAb), which specifically blocks the calcitonin gene-related peptide (GGRP) receptor.
Lucas Hendrik, Overeem, Lars, Neeb, Uwe, Reuter   +2 more
openaire   +2 more sources

Erenumab

Reactions Weekly, 2020
openaire   +2 more sources

Erenumab

Reactions Weekly, 2023
openaire   +2 more sources

Erenumab versus topiramate for the prevention of migraine – a randomised, double-blind, active-controlled phase 4 trial

Cephalalgia, 2022
Uwe Reuter
exaly  

Erenumab in the prevention of high‐frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real‐life study

Headache, 2021
Piero Barbanti, Cinzia Aurilia, Luisa Fofi   +2 more
exaly  

Predicting erenumab adverse events with single-cell genomics

Lancet, The, 2020
Angeliki Vgontzas, William Renthal
exaly  

Hypertension: A new safety risk for patients treated with erenumab

Headache, 2021
Suprat Saely
exaly